12 Yau 3 kwanaki, binciken "The Lancet" da aka buga akan layi, don CD30 - mai mahimmanci na waje T -cell marasa lafiya lymphoma, wannan rituximab, cyclophosphamide, doxorubicin da kuma prednisone ( A + CHP ) Mafi kyau fiye da cyclophosphamide, doxorubicin, vincristine da prednisone ( Sara ).
Steven Horwitz, MD, daga Memorial Sloan Kettering Cancer Center a cikin New York City da abokan aiki suka gudanar da makauniya mai sau biyu, mai sarrafa wuribo, mai sarrafa iko na 3 wanda ya shafi marasa lafiya 452 daga wurare 132 a cikin kasashe 17. Wadannan marasa lafiya CD30- kwayar cutar kwayar cutar kwayar halitta ba tare da kulawa ta farko ba. Marasa lafiya da keɓaɓɓen rabo na bazuwar 1, sun karɓi A + CHP ko na CHOP, sun ci gaba 1, ko. 6 ga 8 shine zagayowar rana.
Masu binciken sun gano cewa rayayyen ci gaba mara kyau (PFS) na kungiyar A + CHP da kungiyar CHOP sun kasance watanni 48.2 da 20.8, bi da bi. Abinda ya faru na illa ya kasance daidai tsakanin ƙungiyoyi biyu, gami da febrile neutropenia (18% da 15%, bi da bi) da kuma neuropathy na gefe (52% da 55%, bi da bi). Mummunan abubuwan da suka faru sun faru a cikin 3% da 4% na marasa lafiya, bi da bi.
In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for linzoma marasa lafiya.
